Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

8295	Companies
114856	Keywords
55300	Articles
62444	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 11/19/2024 at 13:35, 1 day 22 hours ago

Protagonist Therapeutics annonce le développement d'un nouvel antagoniste de l'IL-17

Conférence Téléphonique Produits Biopharmaceutiques Thérapeutique Protagoniste Développement De Peptides Antagoniste De L'IL-17
BRIEF

published on 11/19/2024 at 13:35, 1 day 22 hours ago

Protagonist Therapeutics to Announce New IL-17 Antagonist Development

Conference Call Biopharmaceuticals Protagonist Therapeutics Peptide Development IL-17 Antagonist
PRESS RELEASE

published on 11/19/2024 at 13:30, 1 day 22 hours ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics to host conference call and webcast on November 21st at 4:30 pm ET to announce oral peptide IL-17 antagonist development. Details: dial-in and webcast link provided

Conference Call Webcast Protagonist Therapeutics Oral Peptide IL-17 Antagonist Development Candidate
BRIEF

published on 11/18/2024 at 22:10, 2 days 14 hours ago

Protagonist Therapeutics annonce des résultats positifs de l'essai de phase 3 sur l'icotrokinra dans le traitement du psoriasis

Essais De Phase 3 Thérapeutique Protagoniste Johnson & Johnson Icotrokinra Psoriasis En Plaques
BRIEF

published on 11/18/2024 at 22:10, 2 days 14 hours ago

Protagonist Therapeutics Reports Positive Phase 3 Trial Results for Icotrokinra in Psoriasis

Phase 3 Trials Protagonist Therapeutics Johnson & Johnson Plaque Psoriasis Icotrokinra
PRESS RELEASE

published on 11/18/2024 at 22:05, 2 days 14 hours ago

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Protagonist announces positive Phase 3 ICONIC study results of icotrokinra, a first-in-class oral peptide for plaque psoriasis, achieving key endpoints and milestone payments under Johnson & Johnson collaboration

Phase 3 Plaque Psoriasis Icotrokinra Protagonist ICONIC Study
BRIEF

published on 11/07/2024 at 22:10, 13 days 14 hours ago

Mise à jour financière et étapes cliniques de Protagonist Therapeutics

Résultats Financiers Essais Cliniques Thérapeutique Protagoniste Résultats De La Phase 3 Traitement Du Psoriasis
BRIEF

published on 11/07/2024 at 22:10, 13 days 14 hours ago

Protagonist Therapeutics Financial Update and Clinical Milestones

Financial Results Clinical Trials Protagonist Therapeutics Phase 3 Results Psoriasis Treatment
PRESS RELEASE

published on 11/07/2024 at 22:05, 13 days 14 hours ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports financial results and upcoming milestones for Phase 3 clinical trials in psoriasis and ulcerative colitis, Phase 3 trials in polycythemia vera, and oral peptide antagonist development candidate nomination

Ulcerative Colitis Clinical Trials Protagonist Therapeutics Polycythemia Vera Psoriasis
BRIEF

published on 11/05/2024 at 22:10, 15 days 14 hours ago

Protagonist Therapeutics présentera les données de l'étude de phase 2 lors de la réunion de l'ASH

Étude De Phase 2 Rusfertide Thérapeutique Protagoniste Réunion De L'ASH Polycythémie Vraie

Accesswire

Published on 11/21/2024 at 12:00, 13 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 13 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 43 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 10 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 13 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:06, 6 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 13 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 43 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 12 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 1 hour 13 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 15 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 15 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 15 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 5 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 53 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE